The clinical efficacy of apatinib plus Ba zhen granules in the treatment of advanced unresectable differentiated thyroid cancer and their influence on immune factors | [Pakistan Journal of Pharmaceutical Sciences • 2023]

Author(s):

1. Yang Bai: The Fourth Department of Thyroid and Breast Surgery, Cangzhou Central Hospital,Cangzhou,China

2. Jian Jin: The Fourth Department of Thyroid and Breast Surgery, Cangzhou Central Hospital,Cangzhou,China

3. Yonghong Liu: The Fourth Department of Thyroid and Breast Surgery, Cangzhou Central Hospital,Cangzhou,China

4. Buyong Zhang: The Fourth Department of Thyroid and Breast Surgery, Cangzhou Central Hospital,Cangzhou,China

5. Bo Zhang: The Fourth Department of Thyroid and Breast Surgery, Cangzhou Central Hospital,Cangzhou,China

6. Jie Li: The Fourth Department of Thyroid and Breast Surgery, Cangzhou Central Hospital,Cangzhou,China

Abstract:

The aim of this study was to analyze the clinical efficacy of Apatinib plus Ba Zhen granules in advanced unresectable differentiated thyroid cancer and its influence on immune factors. Sixty patients with advanced unresectable differentiated thyroid cancer in our hospital between January 2018 and December 2019 were selected and randomized to the control group and the observation group (30 cases in each group). After treatment, the observation group yielded higher serum levels of Cyfra21.1 and Gal-3, but lower SIL-2R levels than the control group. After treatment, the two groups obtained a marked increase in CD3+ and CD4+ levels and a decrease in CD8+ level, in which the observation group has higher levels of CD3+ and CD4+ and lower levels of CD8+ than the control group. After treatment, the serum FT3 and FT4 levels sharply increased and serum TSH levels declined significantly, with higher levels of FT3 and FT4 and lower levels of TSH observed in the observation group. The incidence of adverse reactions didn't significantly differ between groups. In advanced unresectable differentiated thyroid cancer, apatinib remarkably inhibits disease development. The combination of Apatinib and Ba Zhen granules adjusts immune factors and improves thyroid function, with a low incidence of adverse reactions and promising efficacy.

Page(s): 935-939

DOI: 10.36721/PJPS.2023.36.3.SP.935-939.1

Published: Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 36, Issue: S3, Year: 2023

Keywords:

Thyroid cancer , thyroid cancer , efficacy , apatinib , Ba Zhen granules , Thyroid Function

References:

[1] Agrawal VR,Jodon G,Mushtaq R,Bowles DW .2018 .Update on multikinase inhibitor therapy for differentiated thyroid cancer. Drugs Today (Barc), 54(9) : 535-545.

[2] Cabanillas ME,McFadden DG,Durante C .2016 .Thyroid cancer. Lancet, 388(10061) : 2783-2795.

[3] Cai S,Deng H,Chen Y,Wu X,Guan X .2017 .Treatment of medullary thyroid carcinoma with apatinib: A case report and literature review. Medicine (Baltimore), 96(50) : e8704.

[4] Chang LS,Barroso-Sousa R,Tolaney SM,Hodi FS,Kaiser UB,Min L UB .2019 .Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr. Rev., 40(1) : 17-65.

[5] Cheng L,Jiao Q,Jin Y,Fu H,Zhang H,Chen L H .2019 .Initial therapy of advanced anaplastic thyroid cancer via targeting VEGFR-2: A case report. , 12 : 10495-10500.

[6] Feng H,Cheng X,Kuang J,Chen L,Yuen S,Shi M,Liang J,Shen B,Jin Z,Yan J,Qiu W .2018 .Apatinib-induced protective autophagy and apoptosis through the AKT-mTOR pathway in anaplastic thyroid cancer. Cell Death Dis., 9 : 1030.

[7] Jin Z,Cheng X,Feng H,Kuang J,Yang W,Peng C,Shen B,Qiu W .2017 .Apatinib inhibits angiogenesis via suppressing Akt/GSK3β/ANG signaling pathway in anaplastic thyroid cancer. Cell Physiol Biochem., 44(4) : 1471-1484.

[8] Lin Y,Wang C,Gao W,Cui R,Liang J .2017 .Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer. Oncotarget., 8(26) : 42252-42261.

[9] Meng X,Wang H,Zhao J,Hu L,Zhi J,Wei S,Ruan X,Hou X,Li D,Zhang J,Yang W,Qian B,Wu Y,Zhang Y,Meng Z,Guan L,Zhang H,Zheng X,Gao M .2020 .Apatinib inhibits cell proliferation and induces autophagy in human papillary thyroid carcinoma via the PI3K/Akt/mTOR signaling pathway. Front Oncol., 10 : 217.

[10] Na KJ,Choi H KJ .2018 .Immune landscape of papillary thyroid cancer and immunotherapeutic implications. Endocr Relat Cancer, 25(5) : 523-531.

[11] Nagayama Y .2018 .Thyroid autoimmunity and thyroid cancer - The pathogenic connection: A 2018 update. Horm Metab Res., 50(12) : 922-931.

[12] Niu Y,Ding Z,Deng X,Guo B,Kang J,Wu B,Fan Y .2020 .A novel multimodal therapy for anaplastic thyroid carcinoma: (125) I seed implantation plus apatinib after surgery. Front Endocrinol (Lausanne), 11 : 207.

[13] Scott LJ .2018 .Apatinib: A review in advanced gastric cancer and other advanced cancers. Drugs, 78 : 747-758.

[14] Su M,Gao Y,Ye X,Zhou Q,Zhao L,Cai X,Chen D,Su H,Zhang X,Xie C .2019 .Clinical value of apatinib as a salvage treatment in patients with chemorefractory advanced cervical cancer. Onco Targets Ther., 12 : 9707-9713.

[15] Tuttle RM .2018 .Controversial issues in thyroid cancer management. J. Nucl. Med, 59(8) : 1187-1194.

[16] Venerito M,Link A,Rokkas T,Malfertheiner P .2016 .Gastric cancer - clinical and epidemiological aspects. Helicobacter, 21(Suppl 1) : 39-44.

[17] Wang C,Zhang X,Yang X,Li H,Cui R,Guan W,Li X,Zhu Z,Lin Y .2018 .PET response assessment in apatinib-treated radioactive iodine-refractory thyroid cancer. Endocr Relat Cancer, 25(6) : 653-663.

[18] Xu J,Shen J,Gu S,Zhang Y,Wu L,Wu J,Shao G,Zhang Y,Xu L,Yin T,Liu J,Ren Z,Xiong J,Mao X,Zhang L,Yang J,Li L,Chen X,Wang Z,Gu K,Chen X,Pan Z,Ma K,Zhou X,Yu Z,Li E,Yin G,Zhang X,Wang S,Wang Q .2021 .Camrelizumab in combination with Apatinib in patients with advanced Hepatocellular carcinoma (RESCUE): A nonrandomized, open-label, Phase II trial. Clin. Cancer Res., 27(4) : 1003-1011.

[19] Zhang X,Wang C,Lin Y .2018 .Pilot Dose Comparison of Apatinib in Chinese patients with progressive radioiodine-refractory differentiated thyroid cancer. J. Clin. Endocrinol. Metab., 103(10) : 3640-3646.

Citations

Downloads

Views